Tandem Diabetes (TNDM) Tops Q2 EPS by 4c

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $21.3 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Goldman "broadly" raises estimates for LTL and truckload stocks
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary